Abstract
In This Issue...
Despite recent improvements in treatment, cancer remains a huge public health
burden. Cytotoxic treatments play a critical role in modern cancer therapy.
Unfortunately, traditional cytotoxic agents are associated with significant
toxicity. In an effort to discover new oncology drugs with improved clinical
benefits and fewer side effects, drug developers have committed substantial
resources to identifying novel cancer targets and compounds that interact with
those targets. These efforts have been facilitated by a plethora of
technologies developed in recent years to generate and exploit genomic and
proteomic information. In this report, we review novel cancer drug targets and
the drugs under development directed at these targets.
View Cart
